Crohn Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
BT-11 significantly decreases interferon gamma positive (IFNγ+) and tumor necrosis factor alpha positive (TNFα+) cluster of differentiation 4 positive (CD4+) T cells and increases forkhead box P3 positive (FOXP3+) CD4+ T cells in colonic lamina propria mononuclear cells from patients with CD and patients with UC at concentrations of 0.01 µM when treated ex vivo.
|
31077582 |
2020 |
Crohn Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
We investigated TNFα regulation by microRNA in Crohn's disease [CD], and studied effects on epithelial permeability and inflammation.
|
31626694 |
2020 |
Crohn Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Postoperative use of anti-TNF agents might reduce the reoperation rate for bionaive patients with CD.
|
31336198 |
2020 |
Crohn Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Tumour necrosis factor-α (TNF-α) inhibitors are increasingly being used as immunomodulators to manage inflammatory conditions such as rheumatoid arthritis and Crohn's disease.
|
31645276 |
2020 |
Crohn Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Treatment with tumor necrosis factor antagonists increased steadily for patients with CD (43.4% of all patients in Brazil were treated in 2014) but less so for patients with UC (4.5% of all patients were treated in 2014).Surgery for IBD decreased with time.
|
31252191 |
2020 |
Crohn Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
The in vivo effects of the SPL inhibitors 4-deoxypyridoxine hydrochloride (30 mg/L) and 2-acetyl-4 (tetrahydroxybutyl)imidazole (50 mg/L) were assessed through their oral administration to adult TNF∆ARE mice, which spontaneously develop Crohn's-like chronic ileitis.
|
31807751 |
2020 |
Crohn Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Higher anti-tumor necrosis factor levels are associated with perianal fistula healing and fistula closure in Crohn's disease.
|
31567638 |
2020 |
Crohn Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Anti-TNF dose escalation and drug sustainability in Crohn's disease: Data from the nationwide administrative database in Hungary.
|
31669077 |
2020 |
Crohn Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Furthermore, in CD, circRNA_103516 correlated positively with CDAI (<i>P</i> < 0.001), CRP (<i>P</i> < 0.001), ESR (<i>P</i> < 0.001), TNF-α (<i>P</i> < 0.001), and IFN-γ (<i>P</i> < 0.001) and negatively correlated with IL-10 (<i>P</i> = 0.006).
|
31749597 |
2019 |
Crohn Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Plasma concentration of TNF-α is higher in patients with Crohn's disease (CD) than healthy controls (HC) and correlates positively with disease activity.
|
30765731 |
2019 |
Crohn Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Circulating JNK pathway-associated phosphatase level correlates with decreased risk, activity, inflammation level and reduced clinical response to tumor necrosis factor-α inhibitor in Crohn disease patients.
|
31415355 |
2019 |
Crohn Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Combination therapy using a combination of anti-TNFα [infliximab] and an immunomodulator is cost-effective in the treatment of Crohn's disease compared with treatment cycles in which the immunomodulator is withdrawn.
|
30893421 |
2019 |
Crohn Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
The optimal timing of treatment escalation in Crohn's disease [CD] remains a challenging issue, and very little is known about its long-term development following early versus late administration of anti-TNF antibodies.
|
30854548 |
2019 |
Crohn Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
This is the first study to suggest that Bangladeshi patients resident in the UK with CD respond less well to treatment with TNF antagonists than Caucasian patients.
|
31655907 |
2019 |
Crohn Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
To describe the use of tumor necrosis factor-alpha inhibitors (TNFis) among pregnancies ending in a live birth and with a diagnosis of ankylosing spondylitis (AS), Crohn's disease (CD), juvenile idiopathic arthritis (JIA), psoriasis (PsO), psoriatic arthritis (PsA), rheumatoid arthritis (RA), or ulcerative colitis (UC).
|
30430682 |
2019 |
Crohn Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In patients with CD who were naive to TNF antagonists, a significantly greater percentage of patients given vedolizumab achieved the predefined score at weeks 2 and 4 compared to those given placebo.
|
29857145 |
2019 |
Crohn Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Earlier Anti-Tumor Necrosis Factor Therapy of Crohn's Disease Correlates with Slower Progression of Bowel Damage.
|
30607690 |
2019 |
Crohn Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Mucosal IL13RA2 expression predicts nonresponse to anti-TNF therapy in Crohn's disease.
|
30663072 |
2019 |
Crohn Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
In clinical practice, anti-TNFs for the prevention of POR of Crohn disease are frequently used in patients experienced with anti-TNFs and with concomitant immunosuppressants.
|
31006801 |
2019 |
Crohn Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
To examine whether there is an increased risk of developing Crohn's disease (CD) and ulcerative colitis (UC) while under treatment with anti-TNFα agents for diseases other than inflammatory bowel disease (IBD) METHODS: A nationwide cohort study, based on Danish health registries, of all patients who utilised anti-TNFα agents for non-IBD indications.
|
31267570 |
2019 |
Crohn Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Early Initiation of Tumor Necrosis Factor Antagonist-Based Therapy for Patients With Crohn's Disease Reduces Costs Compared With Late Initiation.
|
30056180 |
2019 |
Crohn Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
To investigate effects moxibustion exerts on A20 expression and regulation of intestinal epithelial tight junctions via the TNF-α-NF-κB-MLCK pathway in Crohn's disease (CD).
|
31302421 |
2019 |
Crohn Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
We provide evidence that rLeptin exerts diverse pro-inflammatory effects on immune cell differentiation and function, including the metabolic reprogramming of immune cells and the induction of TNFα, ultimately aggravating Crohn's disease in the AGLCD patient, which can be reversed by anti-TNFα therapy.
|
31822667 |
2019 |
Crohn Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Among the patients enrolled, 54.5% had previous failure of 1 or more tumor necrosis factor (TNF) antagonists and 44.6% had severe endoscopic disease activity (SES-CD scores above 15) at baseline.
|
31279871 |
2019 |
Crohn Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Smokers with Crohn s disease have a significantly higher mRNA expression of pro-inflammatory cytokine TNF ?
|
31842582 |
2019 |